Assignment history

Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.

Assignment history

Inventors

Nikolaj Skak: Veloxis Pharmaceuticals Inc. (at time of filing)
Per Holm: Veloxis Pharmaceuticals Inc. (at time of filing)

Original assignee

Veloxis Pharmaceuticals Inc. (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) is a pharmaceutical company that develops and commercializes immunosuppressive drugs. They market products such as Envarsus XR (tacrolimus extended-release tablets) for the prevention of organ rejection in adult kidney transplant patients. Veloxis Pharmaceuticals Inc. is currently operating as a subsidiary of Asahi Kasei Pharma.

Assignment timeline

The USPTO Patent Assignment Search database does not currently show any assignment records for US12403095. The current assignee, Veloxis Pharmaceuticals Inc., is the original assignee as shown on the patent document.

Timeline diagram

timeline
    title Ownership of US 12403095
    2008 : Priority date
    2022 : Application filed by Veloxis Pharmaceuticals Inc
    2025 : Application granted, published to Veloxis Pharmaceuticals Inc

NPE / troll-pattern signals

Shell-entity transfer — not present
Known asserter in the chain — not present
Repeat correspondent across the chain — not present
Cascading transfers — not present
Pre-litigation transfer — not present
Bankruptcy fire-sale — not present
Privateering — not present
Defensive aggregator (anti-NPE) — not present

Verdict

Operating-company assertion

There are no assignment records for US12403095 in the USPTO database, indicating that the patent remains with its original assignee, Veloxis Pharmaceuticals Inc. Veloxis Pharmaceuticals Inc. is a pharmaceutical company that manufactures and sells products related to tacrolimus. The litigation cases initiated by Veloxis Pharmaceuticals Inc. against Glenmark Pharmaceuticals Inc., USA (1:26-cv-00305) and Zydus Pharmaceuticals (USA) Inc. (1:26-cv-00467) appear to be typical operating-company assertions against generic drug manufacturers.

USPTO Assignment Center search: https://assignmentcenter.uspto.gov/